Search Within

Gastrointestinal Oncology Service

Formats
  1. Journal Article (2349)
  2. Meeting Abstract (1870)
  3. Review (150)
  4. Book Section (127)
  5. Editorial (100)
  6. Guidelines (39)
  7. Correspondence (34)
  8. Conference Paper (24)
  9. Miscellaneous (22)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Solid Tumor Oncology Division (4744)
  2. Department of Medicine (4742)
  3. Center for Pancreatic Cancer Research (2312)
  4. Surgery (1065)
  5. Survivorship Research (1013)
  6. Epidemiology and Biostatistics (842)

More Groups

People
  1. Eileen O'Reilly (803)
  2. Leonard Saltz (796)
  3. Ghassan Abou-Alfa (583)
  4. Nancy Kemeny (545)
  5. David Kelsen (538)
  6. David Ilson (443)

More People

Years
  1. 2025 (219)
  2. 2024 (309)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1290)
  2. Annals of Oncology (331)
  3. Annals of Surgical Oncology (147)
  4. Cancer (128)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1379)
  2. Oxford University Press (462)
  3. Elsevier Inc. (408)
  4. Springer (320)
  5. American Association for Cancer Research (281)
  6. Wiley Blackwell (241)

More Publishers

Results (4744)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: A global retrospective study
    Journal Article

    Mazzoli, G.; Nichetti, F.; Shitara, K.; Cohen, R.; Lonardi, S.; Cremolini, C.; Elez, M. E.; Chao, J.; Fakih, M.; Klempner, S. J.; more...
    ESMO Gastrointestinal Oncology (2024)

    Fulltext@MSK | Save
  • The first encounter with oncology: Patient experience and requisite trust
    Book Section

    Ahluwalia, A.; Epstein, A.
    In McFarland, D. C.; Grassi, L.; Silver, S. M.; Riba, M. B. (Eds.) The Complex Role of Patient Trust in Oncology (2024)

    Fulltext@MSK | Save
  • An ancient mechanically-induced neuronal cell state promotes melanoma invasion
    Meeting Abstract

    Hunter, M. V.; Sherman, M. H.; White, R. M.
    Molecular Biology of the Cell (2024)

    Fulltext@MSK | Save
  • Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
    Meeting Abstract

    Park, W.; O'Reilly, E. M.; Li, C. P.; Oh, D. Y.; Garcia-Carbonero, R.; Roth, G.; Nakajima, T.; Moran, D.; Yang, J.; Li, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Total neoadjuvant FLOT chemotherapy in oesophagogastric adenocarcinoma: An international cohort study
    Meeting Abstract

    Clements, H. A.; Dobrzhanskiy, O.; Yang, J.; Bausys, A.; Ferri, L. E.; Ku, G. Y.; Smyth, E. C.; Underwood, T. J.; Petty, R. D.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW
    Meeting Abstract

    Kang, Y. K.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Lordick, F.; Van Cutsem, E.; Ilson, D. H.; Klempner, S. J.; Yamaguchi, K.; Nakajima, T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J.; Schwartz, C.; Larsen, M.; Varghese, A.; Yu, K.; Balogun, F.; Yang, J.; Katz, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • MK-2870-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
    Meeting Abstract

    Wainberg, Z. A.; Van Cutsem, E.; Shitara, K.; Janjigian, Y. Y.; Oh, D. Y.; Xu, J.; Wu, S.; Bhaumik, S.; Bhagia, P.; Tabernero, J.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)
    Meeting Abstract

    Janjigian, Y. Y.; van Laarhoven, H. W. M.; Rha, S. Y.; Kozlov, V.; Oh, D. Y.; Gravina, A.; Rapatoni, L.; Shoji, H.; Hofheinz, R. D.; Chen, L. T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial
    Meeting Abstract

    Elimova, E.; Ajani, J. A.; Burris, H. A.; Denlinger, C. S.; Iqbal, S.; Kang, Y. K.; Kim, J. H.; Lee, K. W.; Lin, B.; Mehta, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save